Previous Close | 4.88 |
Open | 4.87 |
Bid | 4.99 x 200 |
Ask | 5.04 x 400 |
Day's Range | 4.87 - 5.11 |
52 Week Range | 2.13 - 7.73 |
Volume | |
Avg. Volume | 585,527 |
Market Cap | 242M |
Beta (5Y Monthly) | 1.31 |
PE Ratio (TTM) | 11.16 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...
Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.